LP-65

General Information


DRACP ID  DRACP00832

Peptide Name   LP-65

Sequence  IEELLKKAEEQQKKNEEELKKLEX

Sequence Length  24

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Induce apoptosis



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
TZM-bl Human papillomavirus-related endocervical adenocarcinoma Carcinoma 50% Cytotoxicity=256.23±14.58µM CellTiter 96 AQueous One Solution assay 48h 1
MT-4 Human acute lymphoblastic leukemia cell line Leukemia 50% Cytotoxicity=213.4±59.59µM CellTiter 96 AQueous One Solution assay 48h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HEK293T: 50% Cytotoxicity=208.43±22.9 µM; PBMC: 50% Cytotoxicity=49.95±2.97 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  X(24)= Lysine with palmitoylated side group

Chiral  L



Physicochemical Information


Formula  C123H210N32O42

Absent amino acids  CDFGHMPRSTVWY

Common amino acids  E

Mass  332964

Pl  4.6

Basic residues  6

Acidic residues  8

Hydrophobic residues  6

Net charge  -2

Boman Index  -7909

Hydrophobicity  -168.33

Aliphatic Index  85.42

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30089693

Title  Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus

Doi 10.1128/JVI.01088-18

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.